Synaptotoxic amyloid-β oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease pathogenesis; amyloid oligomers; animal models; biomarkers; cellular mechanisms; vaccines

Indexed keywords

AMYLOID BETA PROTEIN; GINKGO BILOBA EXTRACT; GINKGOLIDE; INSULIN; INSULIN RECEPTOR; MEMANTINE; METABOTROPIC RECEPTOR 5; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CELL ACTIVATION; DISEASE MODEL; EXPERIMENTAL MOUSE; GENE DELETION; GLIA; HUMAN; MEMORY; MEMORY DISORDER; MOLECULAR MECHANICS; MOLECULAR MODEL; NERVE CELL; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; TRANSGENIC ANIMAL;

EID: 84872552899     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129039     Document Type: Review

References (162)

1. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260
2. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF (2005) Soluble beta-Amyloid1-40 induces NMDA-Dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25, 11061-11070
3. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807
4. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-Type glutamate receptor-Dependent signaling pathway. J Neurosci 27, 2866-2875
5. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, NairnAC, SalterMW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058
6. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843
7. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, KleinWL(2008) Alzheimer's disease-Type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 29, 1334-1347
8. Jin M, Shepardson N, Yang T, Chen G,Walsh D, Selkoe DJ (2011) Soluble amyloid beta-Protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819-5824
9. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Munoz DP, De Felice FG (2012) An anti-Diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- Associated Abeta oligomers. J Clin Invest 122, 1339-1353
10. Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, Haense C, Herholz K, Nobili F, Reiman EM, Jagust WJ, Frisoni GB, Eadc-Pet Consortium ND, Alzheimer's Disease Neuroimaging I (2012) Summary metrics to assess alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-To-head comparison. J Nucl Med 53, 592-600
11. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-Methyl-Daspartate receptor-Dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601
12. LambertMP, BarlowAK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B,Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453
13. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-Term potentiation in vivo. Nature 416, 535-539
14. Knobloch M, Farinelli M,KonietzkoU, Nitsch RM, Mansuy IM (2007) Abeta oligomer-Mediated long-Term potentiation impairment involves protein phosphatase 1-Dependent mechanisms. J Neurosci 27, 7648-7653
15. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28, 14537-14545
16. Koffie RM, HymanBT, Spires-JonesTL(2011) Alzheimer's disease: Synapses gone cold. Mol Neurodegener 6, 63
17. Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2Bcontaining NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-Amyloid oligomers on long-Term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990
18. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ (2005) The role of cell-Derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33, 1087-1090
19. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357
20. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, Group AAS (2011) Use of florbetapir-PET for imaging beta-Amyloid pathology. JAMA 305, 275-283
21. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200
22. Ferreira ST, Klein WL (2011) The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96, 529-543
23. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K,Yu GQ, Mucke L (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52
24. Zhao WQ, Santini F, Breese R, Ross D, Zhang XD, Stone DJ, Ferrer M, Townsend M, Wolfe AL, Seager MA, Kinney GG, Shughrue PJ, Ray WJ (2010) Inhibition of calcineurin-Mediated endocytosis and alpha-Amino-3-hydroxy-5- Methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 285, 7619-7632
25. DineleyKT, Kayed R, NeugebauerV, FuY, ZhangW, Reese LC, Taglialatela G (2010) Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-Dependent fashion in mice. J Neurosci Res 88, 2923-2932
26. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's diseaseaffected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100, 10417-10422
27. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-Level neuronal expression of abeta 1-42 in wild-Type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058
28. Chauhan NB, Sandoval J, Lambert M, Klein W (2008) ICV anti-ADDL antibody prevented early synaptic deficits in TgCRND8 mouse model of Alzheimer's disease. Alzheimers Dement 4(Suppl), T467-T468
29. Chauhan NB, Xiao C, Davis F, Lambert M, Viola K, Lacor PN, Dravid V, Klein W (2012) Intransal passive immunization using WGA-Modified oligomer antibodies greatly improves learning and memory in Alzheimer's 5xFAD Mice. Alzheimer's Association International Conference (Vancouver), p1-261
30. ScheibelME,Lindsay RD,Tomiyasu U, ScheibelAB(1975) Progressive dendritic changes in aging human cortex. Exp Neurol 47, 392-403
31. Heidenreich KA, Zahniser NR, Berhanu P, Brandenburg D, Olefsky JM (1983) Structural differences between insulin receptors in the brain and peripheral target tissues. J Biol Chem 258, 8527-8530
32. Heidenreich KA, Gilmore PR, Brandenburg D, Hatada E (1988) Peptide mapping on Northern blot analyses of insulin receptors in brain and adipocytes. Mol Cell Endocrinol 56, 255-261
33. Matsumoto H, RhoadsDE(1990) Specific binding of insulin to membranes from dendrodendritic synaptosomes of rat olfactory bulb. J Neurochem 54, 347-350
34. ZhaoW, Chen H, Xu H, Moore E, Meiri N, Quon MJ, Alkon DL (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274, 34893-34902
35. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48, M117-M121
36. Frolich L, Blum-Degen D, Riederer P, Hoyer S (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 893, 290-293
37. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113
38. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S, Rice V, Newcomer JW, Cryer PE (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: A longitudinal study. Behav Neurosci 107, 926-940
39. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M (2004) Plasma levels of amyloid beta-Protein 42 are increased in women with mild cognitive impairment. Neurology 63, 828-831
40. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192
41. Launer LJ (2005) Diabetes and brain aging: Epidemiologic evidence. Curr Diab Rep 5, 59-63
42. Odetti P, Piccini A, Giliberto L, Borghi R, Natale A, Monacelli F, Marchese M, Assini A, Colucci M, Cammarata S, TabatonM(2005) Plasma levels of insulin and amyloid beta 42 are correlated in patients with amnestic mild cognitive impairment. J Alzheimers Dis 8, 243-245
43. Craft S (2006) Insulin resistance syndrome and Alzheimer disease: Pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20, 298-301
44. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338
45. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113
46. Hendricks SA, Agardh CD, Taylor SI, Roth J (1984) Unique features of the insulin receptor in rat brain. J Neurochem 43, 1302-1309
47. Lowe W Jr, LeRoith D (1986) Insulin receptors from guinea pig liver and brain: Structural and functional studies. Endocrinology 118, 1669-1677
48. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45, 1259-1266
49. Cullen WK, Suh YH, Anwyl R, RowanMJ (1997) Block of LTP in rat hippocampus in vivo by beta-Amyloid precursor protein fragments. Neuroreport 8, 3213-3217
50. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177, 125-134
51. Mielke JG, Wang YT (2005) Insulin exerts neuroprotection by counteracting the decrease in cell-Surface GABA receptors following oxygen-glucose deprivation in cultured cortical neurons. J Neurochem 92, 103-113
52. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, Sadoshima J, TrimarcoB(2005) Akt mediates the cross-Talk between beta-Adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 96, 180-188
53. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R (2006) Neuroprotective effects of green and black teas and their catechin gallate esters against beta-Amyloid-induced toxicity. Eur J Neurosci 23, 55-64
54. Ashe KH (2001) Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 8, 301-308
55. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17, 500-506
56. MoloneyAM,Griffin RJ,Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243
57. Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ (2012) (Val(8)) glucagon-Like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-Structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 674, 280-286
58. Lambert MP, Stevens G, Sabo S, Barber K, Wang G, Wade W, Krafft G, Snyder S, Holzman TF, Klein WL (1994) Beta/A4-evoked degeneration of differentiated SHSY5Y human neuroblastoma cells. J Neurosci Res 39, 377-385
59. Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) betaamyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888
60. Michaelis ML, Dobrowsky RT, Li G (2002) Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 19, 289-293
61. PopeW, Enam SA, Bawa N, Miller BE, Ghanbari HA, Klein WL (1993) Phosphorylated tau epitope of Alzheimer's disease is coupled to axon development in the avian central nervous system. Exp Neurol 120, 106-113
62. Avila J, Lucas JJ, Perez M, Hernandez F (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84, 361-384
63. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-Peptide in the brain and cognitive decline. JAMA 283, 1571-1577
64. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders the brain vulnerable to amyloid beta-Protein neurotoxicity. Nat Med 4, 827-831
65. Gotz J, Chen F, van Dorpe J, NitschRM(2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495
66. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-LyN, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25, 9694-9703
67. Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: Amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10, 64-72
68. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17, 118-120
69. Pratico D, Delanty N (2000) Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. Am J Med 109, 577-585
70. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, Smith MA (2005) Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 31, 205-217
71. Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, Smith MA (2006) Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9, 147-153
72. Chong ZZ, Li F, Maiese K (2005) Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 75, 207-246
73. Serrano F, Klann E (2004) Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev 3, 431-443
74. Duchen MR (2004) Roles of mitochondria in health and disease. Diabetes 53(SUPPL1), S96-S102
75. Louzada PR Jr, Paula Lima AC, de Mello FG, Ferreira ST (2001) Dual role of glutamatergic neurotransmission on amyloid beta(1-42) aggregation and neurotoxicity in embryonic avian retina. Neurosci Lett 301, 59-63
76. Kanski J, Varadarajan S, Aksenova M, Butterfield DA (2002) Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-Peptide 1-42-Associated oxidative stress and neurotoxicity. Biochim Biophys Acta 1586, 190-198
77. Morris RG (2001) Episodic-Like memory in animals: Psychological criteria, neural mechanisms and the value of episodic-Like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 356, 1453-1465
78. Schmitt HP (2005) On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses 65, 259-265
79. Schmitt HP (2005) Pouring oil into the fire? On the conundrum of the beneficial effects ofNMDAreceptor antagonists in Alzheimer disease. Psychopharmacology (Berl) 179, 151-153
80. Decker H, Jurgensen S, AdroverMF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST (2010) N-Methyl-D-Aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers. J Neurochem 115, 1520-1529
81. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132
82. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754
83. Decker H, Lo KY, Unger SM, Ferreira ST, Silverman MA (2010) Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-Dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci 30, 9166-9171
84. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, MountHT, Mufson EJ, Salehi A, FahnestockM (2009) Decreased brain-Derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 29, 9321-9329
85. Sperber BR, Leight S, Goedert M, Lee VM (1995) Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197, 149-153
86. Klein WL, De Felice FG, Lacor PN, Lambert MP, ZhaoWQ (2008) Why Alzheimer's is a disease of memory: Synaptic targeting by pathogenic Abeta oligomers (ADDLs). In Synaptic Plasticity and the Mechanism of Alzheimer's Disease, Selkoe DJ, Triller A, Christen Y, eds. Springer-Verlag, pp. 103-132
87. Renner M, Specht CG, TrillerA(2008) Molecular dynamics of postsynaptic receptors and scaffold proteins. Curr Opin Neurobiol 18, 532-540
88. Ehlers MD, Heine M, Groc L, Lee MC, Choquet D (2007) Diffusional trapping of GluR1 AMPA receptors by inputspecific synaptic activity. Neuron 54, 447-460
89. Serge A, Fourgeaud L, Hemar A, Choquet D (2002) Receptor activation and homer differentially control the lateral mobility of metabotropic glutamate receptor 5 in the neuronal membrane. J Neurosci 22, 3910-3920
90. Bomfim TR, Decker H, Talbot K, Silverman M, Klein WL, Ferreira ST, De Felice FG (2010) Insulinotropic stimulation of GLP-1 receptor protects neurons against Alzheimer's toxic Abeta oligomers. Soc Neurosci Abstr, Program No. 556.16/L5
91. Mehta MV, Gandal MJ, Siegel SJ (2011) mGluR5-Antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS One 6, e26077
92. Ohno M, Chang L, TsengW, OakleyH, Citron M, KleinWL, Vassar R, Disterhoft JF (2006) Temporal memory deficits in Alzheimer's mouse models: Rescue by genetic deletion of BACE1. Eur J Neurosci 23, 251-260
93. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM (2006) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281, 1599-1604
94. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282, 23818-23828
95. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30, 4845-4856
96. Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, Vercauteren F, Houle D, Ducatenzeiler A, Klein WL, Glabe CG, Szyf M, CuelloAC(2011) Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr Alzheimer Res 8, 4-23
97. FerrettiMT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC (2012) Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 33, 1329-1342
98. Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fandrich M, Staufenbiel M, Thal DR (2012) Dispersible amyloid beta-Protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: Their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging, doi:10.1016/j.neurobiolaging. 2011.12.032
99. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A,Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, CuelloAC(2010)Anovel transgenic rat model with a full Alzheimer's-Like amyloid pathology displays pre-Plaque intracellular amyloid-beta-Associated cognitive impairment. J Alzheimers Dis 20, 113-126
100. Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC (2009) Intracellular amyloid formation in muscle cells of Abeta-Transgenic Caenorhabditis elegans: Determinants and physiological role in copper detoxification. Mol Neurodegener 4, 2
101. Wu X, Chen K, Yao L, Ayutyanont N, Langbaum JB, Fleisher A, Reschke C, LeeW, Liu X, Alexander GE, Bandy D, Foster NL, Thompson PM, Harvey DJ, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM, Alzheimer's Disease Neuroimaging I (2010) Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. J Neurosci Methods 192, 277-285
102. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33
103. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-Transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421
104. DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, Sereno L, Rodriguez M, Sanchez B, Hyman BT, Gomez-Isla T (2011) Brain oligomeric beta-Amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70, 360-376
105. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18
106. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ (1998) Amyloid-beta peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Res 785, 195-206
107. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: Age-Dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28, 11650-11661
108. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38
109. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, ImagawaM, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008) A new amyloid beta variant favoring oligomerization in Alzheimer's-Type dementia. Ann Neurol 63, 377-387
110. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-Term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containingNMDA receptors. J Neurosci 31, 6627-6638
111. Bastianetto S, Brouillette J, Quirion R (2007) Neuroprotective effects of natural products: Interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem Res 32, 1720-1725
112. Jang MH, Piao XL, Kim JM, Kwon SW, Park JH (2008) Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis. Phytother Res 22, 544-549
113. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK (2008) Development of a smart nanovehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res 25, 2674-2684
114. FengY,Wang XP,Yang SG,Wang YJ, Zhang X, DuXT, Sun XX, Zhao M, Huang L, Liu RT (2009) Resveratrol inhibits beta-Amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30, 986-995
115. Ajit D, Udan ML, Paranjape G, Nichols MR (2009) Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-Alpha production in the THP-1 human monocytic cell line. Biochemistry 48, 9011-9021
116. Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM (2010) Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-Pathway conformers. J Biol Chem 285, 24228-24237
117. Pitt J, Roth W, Lacor P, Smith AB III, Blankenship M, Velasco P, De Felice F, Breslin P, Klein WL (2009) Alzheimer's-Associated Abeta oligomers showaltered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 240, 189-197
118. US Department of Health and Human Services (2011) 2010 Alzheimer's disease progress report: A deeper understanding. NIH Publication No. 11-7829, http:// www.nia.nih.gov/sites/default/files/2010 alzheimers disease progress report. pdf
119. Lopez DelAmoJM, Fink U, DasariM,Grelle G,Wanker EE, Bieschke J, Reif B (2012) Structural properties of EGCGinduced, nontoxic Alzheimer's Disease Abeta oligomers. J Mol Biol, doi: 10.1016/j.jmb.2012.01.013
120. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26, 13102-13113
121. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278, 1327-1332
122. Birks J, Grimley EV, Van Dongen M (2002) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev, CD003120
123. MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14, 77-83
124. Le Bars PL (2003) Magnitude of effect and special approach to Ginkgo biloba extract EGb 761 in cognitive disorders. Pharmacopsychiatry 36(SUPPL1), S44-S49
125. Mazza M, Capuano A, Bria P, Mazza S (2006) Ginkgo biloba and donepezil: A comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 13, 981-985
126. DeKosky ST, Fitzpatrick A, Ives DG, Saxton J,Williamson J, Lopez OL, Burke G, Fried L, Kuller LH, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C, Investigators G (2006) The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 27, 238-253
127. DeKosky ST,Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, BurkeG, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, Ginkgo Evaluation of Memory Study I (2008) Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 300, 2253-2262
128. Barber K, Enam SA, Bodovitz S, Falduto M, Frail D, Klein WL (1995) Particulate forms of APP in the extracellular milieu of cultured cells. Exp Neurol 132, 42-53
129. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-Assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749-12760
130. Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V(2010) Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 120, 661-666
131. Askanas V, Engel WK (2011) Sporadic inclusion-body myositis: Conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse Med 40, e219-e235
132. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 27, 38-41
133. PedersenWA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199, 265-273
134. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-Amyloid in early AD. Neurology 70, 440-448
135. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152
136. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904
137. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrosesweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282, 36275-36282
138. Crump FT, Dillman KS, CraigAM(2001) cAMP-Dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors. J Neurosci 21, 5079-5088
139. Boyer C, Schikorski T, Stevens CF (1998) Comparison of hippocampal dendritic spines in culture and in brain. J Neurosci 18, 5294-5300
140. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer'slinked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976
141. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol 42, 10-21
142. McNay EC, Recknagel AK (2011) Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem 96, 432-442
143. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340, 1314-1320
144. Kim JI, Kim JC, Kang MJ, Lee MS, Kim JJ, Cha IJ (2005) Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: A randomized controlled study. Eur J Clin Nutr 59, 456-458
145. Umeda T, Tomiyama T, Kitajima E, Idomoto T, Nomura S, Lambert MP, Klein WL, Mori H (2012) Hypercholesterolemia accelerates intraneuronal accumulation of Abeta oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci, doi: 10.1016/j.lfs.2011.12.022
146. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38
147. Hyman BT (2011) Amyloid-Dependent and amyloidindependent stages of Alzheimer disease. Arch Neurol 68, 1062-1064
148. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224
149. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG (2012) Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific. J Neurosci 32, 2696-2702
150. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001) Vaccination with soluble Abeta oligomers generates toxicity-Neutralizing antibodies. J Neurochem 79, 595-605
151. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad SciUSA 102, 2273-2276
152. Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127, 2264-2271
153. Chauhan NB (2007) Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 85, 451-463
154. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-Selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281, 4292-4299
155. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid beta-Derived neurotoxins. CNS Neurol Disord Drug Targets 8, 65-81
156. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M, Michikawa M, Takeuchi H, Suzumura A (2009) Microglia activated with the toll-Like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 175, 2121-2132
157. Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ (2010) Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis 7, 131-135
158. Gaspar R, Shughrue PJ, Wang F, Wang W, Zhang N, Zhao W-Q (2012) Anti-ADDL monoclonal antibody and uses thereof, Organization WIP, WO 2012/009442 A2
159. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM (2011) Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 6, e18296
160. Rakover IS, Zabavnik N, Kopel R, Paz-Rozner M, Solomon B (2010) Antigen-Specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope. J Neuroimmunol 225, 68-76
161. Chauhan NB, Davis F, Xiao C (2011) Wheat germ agglutinin enhanced cerebral uptake of anti-Abeta antibody after intranasal administration in 5XFADmice. Vaccine 29, 7631-7637
162. Fiala JC, Spacek J, HarrisKM(2002) Dendritic spine pathology: Cause or consequence of neurological disorders? Brain Res Brain Res Rev 39, 29-54